{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:32:31Z","timestamp":1791235951987,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2013.259","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T10:20:00Z","timestamp":1374142800000},"page":"e728-e728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer"],"prefix":"10.1038","volume":"4","author":[{"given":"J S","family":"Carew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Espitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K R","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S T","family":"Nawrocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"BFcddis2013259_CR1","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos JL . Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682\u20134689.","journal-title":"Cancer Res"},{"key":"BFcddis2013259_CR2","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/jnci\/85.24.1978","volume":"85","author":"ER Fearon","year":"1993","unstructured":"Fearon ER . K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. J Natl Cancer Inst 1993; 85: 1978\u20131980.","journal-title":"J Natl Cancer Inst"},{"key":"BFcddis2013259_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","volume":"3","author":"M Malumbres","year":"2003","unstructured":"Malumbres M, Barbacid M . RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459\u2013465.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2013259_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/14712590903002039","volume":"9","author":"K Kelly","year":"2009","unstructured":"Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M . Reovirus-based therapy for cancer. Expert Opin Biol Ther 2009; 9: 817\u2013830.","journal-title":"Expert Opin Biol Ther"},{"key":"BFcddis2013259_CR5","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1158\/1541-7786.MCR-12-0157","volume":"10","author":"R Maitra","year":"2012","unstructured":"Maitra R, Ghalib MH, Goel S . Reovirus: a targeted therapeutic \u2013progress and potential. Mol Cancer Res 2012; 10: 1514\u20131525.","journal-title":"Mol Cancer Res"},{"key":"BFcddis2013259_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1172\/JCI9871","volume":"105","author":"KL Norman","year":"2000","unstructured":"Norman KL, Lee PW . Reovirus as a novel oncolytic agent. J Clin Invest 2000; 105: 1035\u20131038.","journal-title":"J Clin Invest"},{"key":"BFcddis2013259_CR7","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","volume":"16","author":"C Comins","year":"2010","unstructured":"Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010; 16: 5564\u20135572.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","volume":"16","author":"P Forsyth","year":"2008","unstructured":"Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16: 627\u2013632.","journal-title":"Mol Ther"},{"key":"BFcddis2013259_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cytogfr.2010.02.006","volume":"21","author":"KJ Harrington","year":"2010","unstructured":"Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS . Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21: 91\u201398.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFcddis2013259_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10637-012-9865-z","volume":"31","author":"DG Morris","year":"2012","unstructured":"Morris DG, Feng X, Difrancesco LM, Fonseca K, Forsyth PA, Paterson AH et al. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs 2012; 31: 696\u2013706.","journal-title":"Invest New Drugs"},{"key":"BFcddis2013259_CR11","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127\u20137137.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"MC Coffey","year":"1998","unstructured":"Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332\u20131334.","journal-title":"Science"},{"key":"BFcddis2013259_CR13","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","volume":"17","author":"JE Strong","year":"1998","unstructured":"Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW . The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 1998; 17: 3351\u20133362.","journal-title":"Embo J"},{"key":"BFcddis2013259_CR14","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Dunner K Jr., Boise LH, Chiao PJ, Huang P et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510\u201311519.","journal-title":"Cancer Res"},{"key":"BFcddis2013259_CR15","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","volume":"66","author":"ST Nawrocki","year":"2006","unstructured":"Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr. et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773\u20133781.","journal-title":"Cancer Res"},{"key":"BFcddis2013259_CR16","doi-asserted-by":"publisher","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr., Huang P et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 65: 11658\u201311666.","journal-title":"Cancer Res"},{"key":"BFcddis2013259_CR17","doi-asserted-by":"publisher","first-page":"11099","DOI":"10.1073\/pnas.0404310101","volume":"101","author":"KL Norman","year":"2004","unstructured":"Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW . Reovirus oncolysis: the Ras\/RalGEF\/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099\u201311104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2013259_CR18","doi-asserted-by":"publisher","first-page":"7720","DOI":"10.1038\/sj.onc.1209041","volume":"24","author":"M Shmulevitz","year":"2005","unstructured":"Shmulevitz M, Marcato P, Lee PW . Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005; 24: 7720\u20137728.","journal-title":"Oncogene"},{"key":"BFcddis2013259_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1083\/jcb.200310015","volume":"165","author":"J Hitomi","year":"2004","unstructured":"Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 2004; 165: 347\u2013356.","journal-title":"J Cell Biol"},{"key":"BFcddis2013259_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783\u20131792.","journal-title":"Cancer Res"},{"key":"BFcddis2013259_CR21","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH . Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907\u20134916.","journal-title":"Blood"},{"key":"BFcddis2013259_CR22","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-10-0529","volume":"16","author":"R Rao","year":"2010","unstructured":"Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K et al. Role of C\/EBP homologous protein (CHOP) in panobinostat-mediated potentiation of bortezomib-induced lethal ER stress in mantle cell lymphoma cells. Clin Cancer Res 2010; 16: 4742\u20134754.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/47513","volume":"403","author":"T Nakagawa","year":"2000","unstructured":"Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98\u2013103.","journal-title":"Nature"},{"key":"BFcddis2013259_CR24","first-page":"1218","volume":"9","author":"T Etoh","year":"2003","unstructured":"Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003; 9: 1218\u20131223.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF01314776","volume":"54","author":"G Hashiro","year":"1977","unstructured":"Hashiro G, Loh PC, Yau JT . The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307\u2013315.","journal-title":"Arch Virol"},{"key":"BFcddis2013259_CR26","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/1535-7163.MCT-08-0083","volume":"7","author":"A Pataer","year":"2008","unstructured":"Pataer A, Hu W, Xiaolin L, Chada S, Roth JA, Hunt KK et al. Adenoviral endoplasmic reticulum-targeted mda-7\/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 2008; 7: 2528\u20132535.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2013259_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/ncb1471","volume":"8","author":"C Denoyelle","year":"2006","unstructured":"Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006; 8: 1053\u20131063.","journal-title":"Nat Cell Biol"},{"key":"BFcddis2013259_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2011.145","volume":"22","author":"Y Hu","year":"2012","unstructured":"Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22: 399\u2013412.","journal-title":"Cell Res"},{"key":"BFcddis2013259_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1158\/1078-0432.CCR-10-2159","volume":"17","author":"MP Lolkema","year":"2011","unstructured":"Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011; 17: 581\u2013588.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR30","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1158\/1078-0432.CCR-09-0796","volume":"15","author":"HS Pandha","year":"2009","unstructured":"Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009; 15: 6158\u20136166.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-07-1400","volume":"14","author":"K Twigger","year":"2008","unstructured":"Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008; 14: 912\u2013923.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccr.2011.09.005","volume":"20","author":"DJ Mahoney","year":"2011","unstructured":"Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S et al. Virus\u2013tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 2011; 20: 443\u2013456.","journal-title":"Cancer Cell"},{"key":"BFcddis2013259_CR33","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ccr.2011.10.002","volume":"20","author":"DJ McConkey","year":"2011","unstructured":"McConkey DJ . RAIDDing ER stress for oncolytic viral therapy. Cancer Cell 2011; 20: 416\u2013418.","journal-title":"Cancer Cell"},{"key":"BFcddis2013259_CR34","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pharmthera.2012.02.003","volume":"134","author":"AM Gorman","year":"2012","unstructured":"Gorman AM, Healy SJ, Jager R, Samali A . Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther 2012; 134: 306\u2013316.","journal-title":"Pharmacol Ther"},{"key":"BFcddis2013259_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejphar.2009.06.064","volume":"625","author":"SJ Healy","year":"2009","unstructured":"Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A . Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009; 625: 234\u2013246.","journal-title":"Eur J Pharmacol"},{"key":"BFcddis2013259_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-07-1510","volume":"14","author":"J Qiao","year":"2008","unstructured":"Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14: 259\u2013269.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1476-4598-8-47","volume":"8","author":"S Sei","year":"2009","unstructured":"Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 2009; 8: 47.","journal-title":"Mol Cancer"},{"key":"BFcddis2013259_CR38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/sj.cgt.7700949","volume":"13","author":"N Smakman","year":"2006","unstructured":"Smakman N, van der Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel Rinkes IH, Kranenburg O . Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 2006; 13: 815\u2013818.","journal-title":"Cancer Gene Ther"},{"key":"BFcddis2013259_CR39","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","volume":"18","author":"EM Karapanagiotou","year":"2012","unstructured":"Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C et al. Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18: 2080\u20132089.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2013259_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/gt.2012.68","volume":"20","author":"V Roulstone","year":"2012","unstructured":"Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin\u2013paclitaxel doublet chemotherapy. Gene Ther 2012; 20: 521\u2013528.","journal-title":"Gene Ther"},{"key":"BFcddis2013259_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2407-12-368","volume":"12","author":"K Twigger","year":"2012","unstructured":"Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R et al. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer 2012; 12: 368.","journal-title":"BMC Cancer"},{"key":"BFcddis2013259_CR42","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jcb.21730","volume":"104","author":"PC Liao","year":"2008","unstructured":"Liao PC, Tan SK, Lieu CH, Jung HK . Involvement of endoplasmic reticulum in paclitaxel-induced apoptosis. J Cell Biochem 2008; 104: 1509\u20131523.","journal-title":"J Cell Biochem"},{"key":"BFcddis2013259_CR43","doi-asserted-by":"publisher","first-page":"9100","DOI":"10.1074\/jbc.M210284200","volume":"278","author":"A Mandic","year":"2003","unstructured":"Mandic A, Hansson J, Linder S, Shoshan MC . Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 9100\u20139106.","journal-title":"J Biol Chem"},{"key":"BFcddis2013259_CR44","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/ijc.25412","volume":"127","author":"S Zhao","year":"2010","unstructured":"Zhao S, Wang Y, Cao L, Ouellette MM, Freeman JW . Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer 2010; 127: 2076\u20132087.","journal-title":"Int J Cancer"},{"key":"BFcddis2013259_CR45","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1038\/onc.2011.478","volume":"31","author":"KR Kelly","year":"2012","unstructured":"Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012; 31: 3023\u20133038.","journal-title":"Oncogene"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2013259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2013259","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2013259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T19:08:25Z","timestamp":1672945705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2013259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7]]}},"alternative-id":["BFcddis2013259"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2013.259","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]},"assertion":[{"value":"18 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}